The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes Streeting announced last month that US drug manufacturer Eli Lilly will ...

The headline trial results will be closely monitored by pharmaceutical industry experts. Shares in Novo Nordisk, which ...

Nov 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections. The results ...

Eli Lilly (NYSE ... help control blood sugar levels and appetite. Lilly and its big pharma rival Novo Nordisk today dominate the weight loss drug market, but competition may be on the horizon.

Robert F. Kennedy Jr. would have broad power as HHS secretary to strip vaccine makers' protections against lawsuits ...

Eli Lilly dominates today's market for weight loss drugs, with two blockbusters ... it was well tolerated even at the highest dose of 100 mg daily. A pill format could be a game-changer because ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded companies. Eli Lilly and Company (NYSE: LLY) today announced detailed ...